TRVI (Trevi Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TRVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Michael Thomas Heffernan | Director | MIXED | — | — |
| 2026-06-04 | Edward T Mathers | Director | A | — | — |
| 2026-06-04 | Dominick Colangelo | Director | A | — | — |
| 2026-06-04 | David P Meeker | Director | A | — | — |
| 2026-06-04 | Michael Thomas Heffernan | Director | A | — | — |
| 2026-06-04 | ANNE VANLENT | Director | A | — | — |
| 2026-02-20 | THOMAS SCIASCIA | Chief Scientific Officer | A | — | — |
| 2026-02-20 | Christopher Galletta | See Remarks | A | — | — |
| 2026-02-20 | JENNIFER L GOOD | President & CEO | A | — | — |
| 2026-02-20 | James V Cassella | Chief Development Officer | A | — | — |
| 2026-02-20 | Farrell Simon | Chief Commercial Officer | A | — | — |
| 2026-01-12 | DAVID C HASTINGS | Chief Financial Officer | A | — | — |
| 2025-12-03 | Christopher Galletta | See Remarks | M | — | — |
| 2025-06-13 | Michael Thomas Heffernan | Director | A | — | — |
| 2025-06-13 | ANNE VANLENT | Director | A | — | — |
| 2025-06-13 | Edward T Mathers | Director | A | — | — |
| 2025-06-13 | David P Meeker | Director | A | — | — |
| 2025-06-13 | Dominick Colangelo | Director | A | — | — |
| 2025-06-03 | JENNIFER L GOOD | President & CEO | A | — | — |
| 2025-06-03 | Lisa Delfini | Chief Financial Officer | A | — | — |
| 2025-06-03 | Christopher Galletta | See Remarks | A | — | — |
| 2025-06-03 | Farrell Simon | Chief Commercial Officer | A | — | — |
| 2025-06-03 | THOMAS SCIASCIA | Chief Scientific Officer | A | — | — |
| 2025-03-26 | THOMAS SCIASCIA | Chief Scientific Officer | MIXED | — | — |
| 2025-03-25 | JENNIFER L GOOD | President & CEO | MIXED | — | — |
| 2025-03-12 | Lisa Delfini | Chief Financial Officer | A | — | — |
| 2025-03-12 | THOMAS SCIASCIA | Chief Scientific Officer | A | — | — |
| 2025-03-12 | JENNIFER L GOOD | President & CEO | A | — | — |
| 2025-03-12 | Christopher Galletta | See Remarks | A | — | — |
| 2025-03-12 | Farrell Simon | Chief Commercial Officer | MIXED | — | — |
| 2025-02-20 | Christopher Galletta | See Remarks | A | — | — |
| 2025-02-20 | JENNIFER L GOOD | President & CEO | A | — | — |
| 2025-02-20 | Lisa Delfini | Chief Financial Officer | A | — | — |
| 2025-02-20 | James V Cassella | Chief Development Officer | A | — | — |
| 2025-02-20 | THOMAS SCIASCIA | Chief Scientific Officer | A | — | — |
| 2025-02-20 | Farrell Simon | Chief Commercial Officer | A | — | — |
| 2025-01-10 | Lisa Delfini | Chief Financial Officer | M | — | — |
| 2024-12-17 | Christopher Galletta | See Remarks | M | — | — |
| 2024-10-01 | James V Cassella | Chief Development Officer | A | — | — |
| 2024-09-09 | JENNIFER L GOOD | President & CEO | MIXED | — | — |
| 2024-09-05 | JENNIFER L GOOD | President & CEO | MIXED | — | — |
| 2024-08-29 | David P Meeker | Director | MIXED | — | — |
| 2024-08-21 | THOMAS SCIASCIA | Chief Scientific Officer | MIXED | — | — |
| 2024-08-16 | THOMAS SCIASCIA | Chief Scientific Officer | MIXED | — | — |
| 2024-06-14 | David P Meeker | Director | A | — | — |
| 2024-06-14 | James V Cassella | Director | A | — | — |
| 2024-06-14 | Edward T Mathers | Director | A | — | — |
| 2024-06-14 | Dominick Colangelo | Director | A | — | — |
| 2024-06-14 | Michael Thomas Heffernan | Director | A | — | — |
| 2024-06-14 | ANNE VANLENT | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 10,421,428 | — |
| — | 10%+ Owner | 6,324,319 | — |
| — | 10%+ Owner | 5,938,562 | — |
| — | 10%+ Owner | 4,824,319 | — |
| — | 10%+ Owner | 4,754,721 | — |
| — | 10%+ Owner | 4,438,562 | — |
| — | 10%+ Owner | 4,438,562 | — |
| — | 10%+ Owner | 3,888,452 | — |
| — | 10%+ Owner | 2,938,562 | — |
| — | Director | 1,151,544 | — |
| — | 10%+ Owner | 1,063,408 | — |
| — | 10%+ Owner | 948,948 | — |
| — | 10%+ Owner | 948,948 | — |
| — | 10%+ Owner | 948,948 | — |
| — | Director | 948,948 | — |
| — | 10%+ Owner | 776,544 | — |
| — | Director | 685,012 | — |
| — | 10%+ Owner | 347,157 | — |
| — | 10%+ Owner | 347,156 | — |
| — | 10%+ Owner | 232,963 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRVI quote page; the site-wide leaderboard is on the insider transactions hub.